Showing 9,101 - 9,120 results of 18,171 for search 'significantly ((((teer decrease) OR (((we decrease) OR (a decrease))))) OR (linear decrease))', query time: 0.53s Refine Results
  1. 9101

    Data Sheet 1_Impact of meteorological factors on influenza incidence in Wuxi from 2014 to 2019: a time series and comprehensive analysis.docx by Menglan He (3768739)

    Published 2025
    “…The exposure-response relationship was analyzed using a generalized additive model. Then we performed subgroup analysis based on age and gender. …”
  2. 9102

    Data Sheet 1_Burden of falls in China, 1992–2021 and projections to 2030: a systematic analysis for the global burden of disease study 2021.xlsx by Liang Sui (20912441)

    Published 2025
    “…Joinpoint regression analysis revealed fluctuating trends in prevalence and incidence with periods of increase and decline, and a general decrease in mortality except during brief intervals. …”
  3. 9103

    Data_Sheet_1_Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice.docx by Ana Laura M. R. Tomiyama (16902930)

    Published 2024
    “…Disease progression upregulated gene transcripts for pro- and anti-inflammatory cytokines, and IFN β treatment significantly decreased mRNA expression for IL4. Overall, the present results demonstrate that a low dosage of IFN β shows therapeutic potential by increasing MHC-I expression, resulting in neuroprotection and immunomodulation.…”
  4. 9104
  5. 9105

    Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

    Published 2024
    “…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”
  6. 9106

    Data Sheet 3_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  7. 9107

    Data Sheet 2_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  8. 9108

    Data Sheet 1_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  9. 9109

    Data Sheet 4_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  10. 9110

    Supplementary Material for: Impact of Ketogenic Diet on Weight, Metabolic, and Endocrine Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis by figshare admin karger (2628495)

    Published 2025
    “…The results of the meta-analysis showed that after KD the patients had a significant weight loss (standard mean difference or SMD 1.31 Kg [95% CI 0.45, 2.17] p=0.003) and lower BMI (SMD 1.27 kg/m2 [95% CI 0.71, 1.83], p<0.001). …”
  11. 9111

    Data Sheet 1_Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3.docx by Adina-Gabriela Vasilescu (22236073)

    Published 2025
    “…Introduction<p>Ovarian Cancer remains a significant global health concern, with high mortality rates, largely due to late-stage diagnosis and limited treatment options. …”
  12. 9112

    Supplementary tables: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  13. 9113

    Data Sheet 1_Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-an... by Junjie Lin (8379594)

    Published 2025
    “…When compared to combination therapy, GCs monotherapy was associated with a reduction in ICU length of stay [SMD −0.25, 95% CI (−0.85, 0.36)], duration of fever (SMD [−0.42, 95% CI (−0.73, −0.11)], and duration of inotropic support [SMD −0.13, 95% CI (−0.46, 0.20)], as well as a decrease in the incidence of left ventricular (LV) dysfunction [OR 0.96, 95% CI (0.55, 1.68)]. …”
  14. 9114

    Supplementary data: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  15. 9115

    Table 1_Has carbon finance been able to promote clean energy development? — a low-carbon technology innovation perspective.xlsx by Rui Cui (622759)

    Published 2025
    “…It is found that carbon finance significantly promotes clean energy development, but this contribution decreases with the intervention of low-carbon technology innovation. …”
  16. 9116

    Data Sheet 1_Effectiveness of community-based management models in chronic obstructive pulmonary disease: a systematic review and meta-analysis.docx by Miao Zhan (2625718)

    Published 2025
    “…Notably, neither approach demonstrated a statistically significant advantage in improving quality of life among COPD populations, as assessed by the St. …”
  17. 9117

    Data Sheet 1_Artificial intelligence-assisted delineation for postoperative radiotherapy in patients with lung cancer: a prospective, multi-center, cohort study.docx by Ziming Han (19926057)

    Published 2024
    “…In addition to better contouring accuracy, the AI-assisted delineation significantly decreased the consuming time and improved the efficiency.…”
  18. 9118
  19. 9119

    Image 3_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.jpeg by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”
  20. 9120

    Table 1_VdPAT1 encoding a pantothenate transporter protein is required for fungal growth, mycelial penetration and pathogenicity of Verticillium dahliae.xlsx by Stephen Mwangi Kamau (20576060)

    Published 2025
    “…In previous study, we identified a pantothenate transporter gene (VdPAT1) in V. dahliae which can be induced by root exudates from a susceptible cotton variety.…”